Veteran railroad executive brings nearly three decades of leadership experience spanning safety, operations, mechanical, transportation, and business growth.

JACKSONVILLE, Fla., Sept. 10, 2026 /PRNewswire/ -- Today, Patriot Rail Company announced the appointment of Jason Bradt as Chief Operating Officer (COO), strengthening the company's leadership team as it continues to expand its railroad, transload, logistics, and excursion operations across the United States.

Bradt will succeed longtime railroad executive Jerry Hall, who will retire at the end of 2026, following an accomplished career and significant contributions to Patriot Rail.

"Jerry's impact on Patriot Rail extends far beyond the railroads and operations he helped lead," said Brandy Christian, President and Chief Executive Officer of Patriot Rail. "His leadership, partnership, and dedication to our employees, customers, and communities have helped shape Patriot Rail into the company it is today. We are grateful for his many contributions and look forward to celebrating his remarkable career in the months ahead."

Following a comprehensive search process, Patriot Rail selected Bradt to help lead the company's next chapter of operational growth.

Bradt brings nearly 30 years of railroad experience and has held leadership roles across safety, transportation, mechanical, engineering and maintenance, customer service, commercial development, and strategic growth. Throughout his career with Genesee & Wyoming and CSX, he has built strong teams, improved safety performance, strengthened customer relationships, and supported business expansion.

"What stood out about Jason was the breadth of his experience and his commitment to people," said Christian. "He is a leader who understands every aspect of the railroad business. Just as importantly, he believes in developing leaders, building strong teams, and creating a culture where employees can succeed. Those values align closely with who we are at Patriot Rail and where we are headed as a company."

As COO, Bradt will oversee operating functions across Patriot Rail's network and work closely with company leadership to drive service excellence, strengthen customer relationships, develop future leaders, and advance strategic growth initiatives.

"I'm honored to join Patriot Rail at such an exciting time in the company's evolution," said Bradt. "Patriot Rail has built a strong reputation for operational excellence, customer service, and investing in its people. I look forward to working alongside employees across the network to build on that foundation, strengthen our operations, and help create new opportunities for growth for our customers, employees, and the communities we serve."

The leadership transition comes as Patriot Rail continues investing in its railroads, transload facilities, logistics capabilities, and excursion operations while pursuing new opportunities for growth throughout its network.

"Patriot Rail is well-positioned for the future," added Christian. "We have talented people, a clear vision, and exciting opportunities ahead. Jason's experience and leadership will help us continue building on the strong foundation already in place as we create value for our customers, employees, and communities."

About Patriot Rail Company:

Patriot Rail is a short line and regional rail service provider in the United States, operating 31 short line railroads, four excursion railways, and a range of customer support services, including transloading, railcar storage, real estate support, and logistics planning. Patriot Rail's principal operations include rail freight transportation and ancillary rail services across more than 1,200 miles of track in 23 states. For more information, visit patriotrail.com.

Media Contact:

Laura Mellem

[email protected]

904-952-2414

SOURCE Patriot Rail Company LLC

Share this article

RENTON, Wash., Sept. 10, 2026 /PRNewswire/ -- The Renton Highlands neighborhood welcomes a new standard of residential living with the grand opening of Maple Highlands, a new community by Conner Homes. This intimate and quiet neighborhood of just 12 single-family homes offers spacious floor plans, large lots, and the craftsmanship of a locally owned builder with more than 65 years of experience. Beginning Saturday, September 12, potential homebuyers can enjoy refreshments, tour a fully furnished model home and take advantage of a $50,000 Buyer Bonus. Tours are available 2 PM to 5 PM at 6270 SE 5th Place, Renton, WA 98059.

"Maple Highlands is a special community because it brings together all the things today's homebuyers are looking for—spacious homes, large homesites, flexible floor plans, and a location that offers both a quiet residential setting and convenient access to everything. We're excited to welcome people to Maple Highlands and give them the opportunity to experience the community for themselves," said Erin Fowler, President of Conner Homes.

Modern Architecture and Flexible Layouts

New homes at Maple Highlands range from 3,256 to 3,798 square feet, featuring contemporary two-story elevations and expansive lots—features that are increasingly difficult to find in new home construction. Residents will have plenty of room for outdoor entertaining, with large covered rear patios that flow into fully fenced and professionally landscaped backyards. Homes will start in the $1.6M's.

Multigenerational Living: Many plans feature main-floor bedrooms with private baths, providing accessibility and privacy for extended family members and guests.

(Extra) Large Garages: Select homes include five-car tandem garages, a rare feature designed to accommodate multiple vehicles while providing significant additional storage space.

Lifestyle Amenities: Interior spaces include expansive windows throughout, designer chosen finishes s, quality appliances, pocket offices, walk-in pantries, mudrooms, and covered front porches and patios that extend the home's living and entertaining space.

Convenient Renton Highlands Location

Maple Highlands is positioned for convenient regional connectivity. Located in the Renton Highlands, the community offers direct access to SR-169 and I-405, as well as nearby shopping centers and grocery stores. Residents are close to seven local parks and the shopping and dining options at The Landing, while golfers will appreciate Maplewood Golf Course, less than 15 minutes away.

Maple Highlands represents the latest addition to Conner Homes' portfolio of active communities, continuing the builder's mission to create neighborhoods that offer value through thoughtful design, quality construction, and proximity to essential services and recreation.

About Conner Homes

Conner Homes' mission is to create great neighborhoods and customer experiences. The company has been designing and building homes for over 65 years and is one of the few remaining local homebuilders in the Seattle area. Conner Homes builds townhomes and single-family homes and currently has seven open communities, with additional communities opening this year. For more information about Conner Homes, visit www.connerhomes.com. 

Conner Homes is an Equal Housing Opportunity Builder.

Contact: [email protected]

SOURCE Conner Homes

Share this article

MENLO PARK, Calif., Sept. 10, 2026 /PRNewswire/ -- The Meta Platforms, Inc. (Nasdaq: META) board of directors today declared a quarterly cash dividend of $0.525 per share of the company's outstanding Class A common stock and Class B common stock, payable on September 28, 2026 to stockholders of record as of the close of business on September 21, 2026.

About Meta

Meta is building the future of human connection, powered by artificial intelligence and immersive technologies. When Facebook launched in 2004, it changed the way people connect. Apps like Messenger, Instagram, and WhatsApp further empowered billions around the world. Now, Meta is moving toward building experiences that foster deeper connections and unlock new possibilities.

Contacts

Investors:

Chad Heaton

[email protected] / investor.atmeta.com

Press:

Matt Tye

[email protected] / meta.com/news

SOURCE Meta

Share this article

Enigmata Emerges from Stealth with $6.5 Million to Let AI Learn Without Exposing Sensitive Data

Enigmata Cipher runs AI directly on encrypted data at production speed, turning the world's locked-away data into fuel for AI

NASHVILLE, Tenn., Sept. 10, 2026 /PRNewswire/ -- Enigmata, Inc. emerged from stealth today with $6.5 million in seed funding led by Blockchange Ventures to commercialize Enigmata Cipher™, a patent-pending cryptographic technology that lets artificial intelligence train, search, and analyze data while it remains encrypted.

Cipher is designed for AI workflows where sensitive data would otherwise be exposed, including model training on proprietary datasets, enterprise use of third-party AI systems, semantic search, analytics, and agentic applications.

The world's most valuable data is often the hardest to use. Clinical records that could improve cancer detection, transaction histories that could help stop fraud, and archives that could train more capable models are locked inside institutions that cannot risk exposing them. Cipher gives organizations a way to put that data to work in AI while keeping it protected.

Cryptographers have pursued computation on encrypted data for decades. Existing approaches have historically forced trade-offs among flexibility, performance, and security. Enigmata Cipher takes a different approach designed around the speed, cost, and flexibility modern AI workloads require.

Cipher transforms records, documents, and datasets into an encrypted form that AI, analytics, and search tools can use on existing enterprise hardware. Because the technology simultaneously structures and encrypts data, it can also improve performance. In Enigmata's internal benchmarks, models trained on Cipher-protected data matched the accuracy of models trained on raw data while completing training 8% to 10% faster. Cipher also supports targeted removal of individual records without retraining a model from scratch, which can help organizations respond to data-deletion requests.

"Every era of computing has forced a choice between using data and protecting it. Enigmata Cipher ends that trade-off," said Scott Searle, co-founder and CEO of Enigmata. "The world's most valuable data no longer has to stay locked away to stay protected. When hospitals, banks, and publishers can safely use their most sensitive assets in AI, we stop asking what AI is allowed to know and start asking what it can safely discover, prevent, and create."

Enigmata's long-term vision is to extend Cipher into infrastructure for secure data licensing. Institutions could make encrypted datasets available for AI training under enforceable usage terms while retaining control of the underlying assets. As copyright disputes reshape how AI companies access training data, Cipher could give data owners a way to participate directly in the value their data creates.

"Privacy is the next great frontier for AI," said Matt Immerso, general partner at Blockchange Ventures. "Every advance in hardware and models only matters if customers are comfortable putting their most sensitive data into AI. Enigmata built encryption for exactly that, from the ground up. We believe Enigmata Cipher will become a core pillar of the AI data economy, defining how sensitive data is used, licensed, and monetized in the AI era."

Enigmata Cipher is now available to selected enterprise design partners. Organizations can request access at enigmata.xyz.

ABOUT ENIGMATA

Enigmata, Inc. is trust infrastructure for the AI data economy. The company's patent-pending core technology, Enigmata Cipher, lets organizations use sensitive data with AI without exposing plaintext to models or processing infrastructure, enabling AI and analytics to operate directly on encrypted data at production speed. Founded in 2024, Enigmata is built for banks, insurers, health systems, life sciences organizations, publishers, data providers, and model owners with valuable data they cannot safely expose but need to use in AI workflows. Learn more at enigmata.xyz.

ABOUT BLOCKCHANGE VENTURES

Blockchange Ventures is a venture capital firm founded in 2017 to capitalize on the investment opportunity created by blockchain technology. The firm manages approximately $900 million in assets and has returned nearly $1 billion to investors. Blockchange partners with visionary, entrepreneurial founders building large, enduring companies at the intersection of blockchain's technological promise and commercial reality.

SOURCE Enigmata

Share this article

Tencent Music Entertainment Group Announces Closing of US$1,000 Million Notes Offering

SHENZHEN, China, Sept. 10, 2026 /PRNewswire/ -- Tencent Music Entertainment Group ("TME," or the "Company") (NYSE: TME and HKEX: 1698), the leading all-in-one music and audio entertainment platform in China, today announced the closing of its public offering of US$1,000 million aggregate principal amount of senior unsecured notes consisting of US$500 million of 5.050% notes due 2031 and US$500 million of 5.650% notes due 2036. The notes have been registered under the U.S. Securities Act of 1933, as amended, and are expected to be listed on The Stock Exchange of Hong Kong Limited on September 11, 2026.

The Company received net proceeds from the offering of approximately US$991.9 million, after deducting underwriting discounts and commissions and estimated offering expenses. The Company intends to use the net proceeds from the offering for general corporate purposes, including refinancing of offshore indebtedness and share repurchases.

The joint bookrunners of the offering are J.P. Morgan Securities LLC, Goldman Sachs (Asia) L.L.C. and The Hongkong and Shanghai Banking Corporation Limited. The joint lead managers of the offering are UBS AG Hong Kong Branch, Bank of China Limited and MUFG Securities Asia Limited.

The Company has an automatic shelf registration statement on Form F-3 (including a base prospectus) on file with the U.S. Securities and Exchange Commission (the "SEC") and has filed the related prospectus supplement with the SEC for the offering of the notes. The offering is being made only by means of the prospectus supplement and accompanying base prospectus. Before you invest, you should read the prospectus supplement and accompanying base prospectus and other documents that the Company has filed with the SEC for more complete information about the Company and the offering. You may obtain these documents free of charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the Company, any underwriter or any dealer participating in the offering will arrange to send an investor the prospectus if the investor requests it by calling J.P. Morgan Securities LLC located at 270 Park Ave, New York, NY 10017, USA at +1-212-834-4533, Goldman Sachs & Co. LLC, an affiliate of Goldman Sachs (Asia) L.L.C., located at 200 West Street, New York, NY 10282, USA at +1-866-471-2526 or The Hongkong and Shanghai Banking Corporation Limited, located at L17, HSBC Main Building, 1 Queen's Road Central, Hong Kong at +1-866-811-8049.

This announcement is not an offer of the securities for sale in the United States and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities referred to herein have not been and will not be registered under the applicable securities laws of any jurisdiction outside of the United States.

About Tencent Music Entertainment

Tencent Music Entertainment Group (NYSE: TME and HKEX: 1698) is the leading all-in-one music and audio entertainment platform in China, operating the country's highly popular and innovative music and audio apps: QQ Music, Kugou Music, Kuwo Music, WeSing and Ximalaya. TME's mission is to create endless possibilities with music and technology. Powered by its content-and-platform dual-engine strategy, TME's expansive offerings extend the value of IP beyond online streaming into offline concerts, artist merchandise, and other IP-centric experiences. TME continuously innovates to deliver a seamless experience where users can discover, listen, sing, watch, perform, and connect across diverse scenarios, while unlocking the enduring value of music and audio IP. For more information, please visit ir.tencentmusic.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the SEC and the HKEX. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Investor Relations Contact

Tencent Music Entertainment Group

[email protected]

+86 (755) 8601-3388 ext. 885034

SOURCE Tencent Music Entertainment Group

Share this article

Bernabei & Kabat: Current KB Home Sales Agent Sues, Alleging Years of Sexual Harassment, Retaliation and Unequal Pay

Federal lawsuit by Las Vegas employee asserting years of sexual harassment and retaliation by KB Home.

LAS VEGAS, Sept. 10, 2026 /PRNewswire/ -- Stephanie Cherney, a Lead Area Sales Representative for KB Home in Las Vegas, has filed a federal lawsuit alleging years of sexual harassment and coercion by a former manager and retaliation by company management after she ended the coerced sexual relationship and reported discrimination.

Cherney, whom KB Home named one of its top 10 sales counselors companywide in FY2024, remains employed by the company. Her lawsuit, filed on July 22, 2026, in the U.S. District Court for the District of Nevada, asserts claims under Title VII of the Civil Rights Act, the Nevada Fair Employment Practices Act and the Equal Pay Act.

According to the complaint, Cherney was subjected to years of unwanted and coercive sexual conduct and denied advancement opportunities. The lawsuit alleges that after Cherney refused to have sex with her manager, management retaliated against her by lowering her performance rating, interfering with sales opportunities, denying pricing concessions available to other salespeople, and stopping her advancement.

"Ms. Cherney has continued to excel at her job while enduring years of sexual harassment, retaliation and unequal treatment," said Lynne Bernabei, counsel for Cherney. "The allegations raise serious questions about KB Home's failure to stop the harassment and retaliation after upper management was notified."

The case is Cherney v. KB Home et al., Case No. 2:26-cv-02225, in the U.S. District Court for the District of Nevada.

Contact:

Lynne Bernabei

[email protected]

(202) 745-1942

SOURCE Bernabei & Kabat, PLLC

Share this article

IRVING, Texas, Sept. 10, 2026 /PRNewswire/ -- Vistra Corp. (NYSE: VST) (the "Company" or "Vistra") announced today the pricing of an underwritten public offering (the "Offering") of $850 million aggregate principal amount of Series A junior subordinated notes due 2057 at a price to the public of 100.000% of their face value (the "Series A Notes") and $650 million aggregate principal amount of Series B junior subordinated notes due 2057 at a price to the public of 100.000% of their face value (the "Series B Notes" and, together with the Series A Notes, the "Notes"). The Notes will be junior subordinated, unsecured obligations of Vistra Operations Company LLC, a Delaware limited liability company and an indirect wholly owned subsidiary of the Company (the "Issuer"). The Notes will be irrevocably and unconditionally guaranteed by the Company. Initially, the Series A Notes will bear interest at an annual rate of 7.00% and the Series B Notes will bear interest at an annual rate of 7.25%.

The Issuer intends to use the net proceeds of the Offering for general corporate purposes, including to make distributions to Vistra to fund the redemption of some or all of Vistra's outstanding 8.0% Series A Fixed-Rate Reset Cumulative Redeemable Perpetual Preferred Stock and 7.0% Series B Fixed-Rate Reset Cumulative Redeemable Green Perpetual Preferred Stock, upon or following their respective five-year reset dates in October 2026 and December 2026. Pending use of the net offering proceeds as described above, the Issuer intends to invest the net proceeds in short-term interest-bearing accounts, securities or similar investments.

The Offering is expected to close on September 24, 2026, subject to customary closing conditions.

Barclays, BofA Securities, Mizuho, MUFG, Truist Securities, BBVA, BMO Capital Markets, Citigroup, Credit Agricole CIB, Goldman Sachs & Co. LLC, J.P. Morgan, Morgan Stanley, Natixis, PNC Capital Markets LLC, RBC Capital Markets, Santander, Scotiabank, SMBC Nikko, SOCIETE GENERALE, Wells Fargo Securities, KeyBanc Capital Markets and US Bancorp are acting as joint book-running managers for the Offering.

The Offering is being made pursuant to an effective shelf registration statement that was filed with the Securities and Exchange Commission ("SEC") on September 9, 2026. The Offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and may be obtained for free by visiting the SEC's website at www.sec.gov. A final prospectus supplement relating to the offering will be filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus can be obtained, when available, from: Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847, or by email at [email protected]; BofA Securities, Inc., Attn: Prospectus Department, 201 North Tryon Street, NC1-022-02-25, Charlotte NC 28255-0001, by telephone at (800) 294-1322, or by e-mail: [email protected]; Mizuho Securities USA LLC, Attention: Debt Capital Markets, 1271 Avenue of the Americas, New York, NY 10020, by telephone at (866) 271-7403, or by email at [email protected]; MUFG Securities Americas Inc., Attn: Capital Markets Group, 1221 Avenue of the Americas, 6th Floor, New York, NY 10020, or by telephone at (877) 649-6848; and Truist Securities, Inc., Attn: Prospectus Department, 740 Battery Avenue SE, 3rd Fl, Atlanta, Georgia 30339 or by telephone at 1-800-685-4786.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy the securities described above, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Vistra

Vistra (NYSE: VST) is a leading, Fortune 500 integrated retail electricity and power generation company based in Irving, Texas, that provides essential resources to customers, businesses, and communities from California to Maine. Vistra is a leader in transforming the energy landscape, with an unyielding focus on reliability, affordability, and sustainability. The company safely operates a reliable, efficient power generation fleet of natural gas, nuclear, coal, solar, and battery energy storage facilities while taking an innovative, customer-centric approach to its retail business.

Cautionary Note Regarding Forward-Looking Statements

The information presented herein includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which are based on current expectations, estimates and projections about the industry and markets in which Vistra operates and beliefs of and assumptions made by Vistra's management, involve risks and uncertainties, which are difficult to predict and are not guarantees of future performance, that could significantly affect the financial results of Vistra. All statements, other than statements of historical facts, that are presented herein, or in response to questions or otherwise, that address activities, events or developments that may occur in the future, including such matters as activities related to our financial or operational projections, financial condition and cash flows, projected synergy, net debt targets, capital allocation, capital expenditures, liquidity, projected Adjusted EBITDA to free cash flow conversion rate, dividend policy, business strategy, competitive strengths, goals, future acquisitions or dispositions, development or operation of power generation assets, market and industry developments and the growth of our businesses and operations, including potential transactions with large load facilities at our nuclear and natural gas plants (often, but not always, through the use of words or phrases, or the negative variations of those words or other comparable words of a future or forward-looking nature, including, but not limited to: "intends," "plans," "will likely," "unlikely," "believe," "confident," "expect," "seek," "anticipate," "estimate," "continue," "will," "shall," "should," "could," "may," "might," "predict," "project," "forecast," "target," "potential," "goal," "objective," "guidance," "on track" and "outlook"), are forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. Although Vistra believes that in making any such forward-looking statement, Vistra's expectations are based on reasonable assumptions, any such forward-looking statement involves uncertainties and risks that could cause results to differ materially from those projected in or implied by any such forward-looking statement, including, but not limited to: (i) adverse changes in general economic or market conditions (including changes in interest rates) or changes in political conditions or federal or state laws and regulations; (ii) the ability of Vistra to execute upon its contemplated strategic, capital allocation, performance, and cost-saving initiatives and to successfully integrate acquired businesses, including our ability to close the acquisition of Cogentrix Energy; (iii) actions by credit ratings agencies; (iv) the severity, magnitude and duration of extreme weather events, contingencies and uncertainties relating thereto, most of which are difficult to predict and many of which are beyond our control, and the resulting effects on our results of operations, financial condition and cash flows; and (v) those additional risks and factors discussed in reports filed with the SEC by Vistra from time to time, including the uncertainties and risks discussed in the sections entitled "Risk Factors" and "Forward-Looking Statements" in Vistra's annual report on Form 10-K for the year ended December 31, 2025 and subsequently filed quarterly reports on Form 10-Q.

Any forward-looking statement speaks only at the date on which it is made, and except as may be required by law, Vistra will not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date on which it is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible to predict all of them; nor can Vistra assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement.

SOURCE Vistra Corp

Share this article

Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults

Phase 3 study demonstrates benefits of the first influenza vaccine to combine three proven approaches to enhancing protection for older adults in a single vaccine.

MAIDENHEAD, United Kingdom, Sept. 10, 2026 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL; USOTC: CSLLY), today announced publication of pivotal Phase 3 study results for its MF59®-adjuvanted cell-based higher-dose quadrivalent influenza vaccine (aQIVc) in The Lancet Infectious Diseases, marking an important milestone in the evolution of influenza prevention for older adults.1

The publication follows approval of the trivalent formulation of aQIVc by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom earlier this year for adults aged 50 years and older.2 The vaccine, marketed as AUJEMFLU®, has also been approved by the European Commission for adults aged 50 years and above.

The peer-reviewed publication reports findings from a large-scale study of the first influenza vaccine to combine three proven approaches to enhancing protection in older adults: MF59® adjuvant, cell-based manufacturing, and a higher dose formulation compared to standard influenza vaccines.1,3

Each of these approaches has been used separately in influenza vaccines for many years and is supported by extensive clinical and real-world evidence. This publication provides the first large-scale evaluation of their combination within a single vaccine.1,2

Influenza remains a significant public health challenge, causing substantial illness, hospitalisations and deaths each year despite widespread vaccination programmes.4

Older adults are particularly vulnerable because the immune system becomes less responsive with age, reducing its ability to mount a strong protective response following vaccination.5

aQIVc combines three proven approaches to enhancing vaccine protection in older adults, with each playing a distinct and complementary role. Cell-based manufacturing helps preserve a closer match to circulating influenza strains, MF59® adjuvant strengthens, broadens and lengthens the immune response and a higher dose formulation further optimises that response.2,6,7,8

The Phase 3 randomised immunogenicity and safety study enrolled 7,699 adults aged 50 years and older across eight countries and compared aQIVc with two enhanced influenza vaccines. The study met its primary objectives and demonstrated:1

- Superiority versus the adjuvanted egg-based influenza vaccine comparator across all four influenza strains and age groups assessed.

- Non-inferiority versus a recombinant influenza vaccine for three out of four strains in the 50+ age group and four out of four strains in those aged 65+.

- Immune responses that persisted throughout the influenza season.

- A well-tolerated safety profile. Most reactions were mild or moderate and resolved within three days.1

The publication also reported exploratory findings of enhanced neuraminidase antibody responses versus comparators. The role of neuraminidase antibodies is an emerging area of influenza research that may contribute to reduced disease severity and broader protection beyond traditional measures of vaccine response.9

The study authors concluded that the findings support further evaluation of the vaccine and provide evidence for National Immunisation Technical Advisory Groups considering enhanced influenza vaccination strategies for older adults.1

Regulatory submissions for the trivalent formulation of aQIVc have been made in multiple markets, with introductions expected to occur through a phased approach aligned to local regulatory, policy and access pathways.

Gregg Sylvester, Chief Medical Officer and Head of Research & Development, CSL Seqirus, said:

"Publication in The Lancet Infectious Diseases is a significant milestone for CSL Seqirus and reflects decades of investment in influenza vaccine innovation."

"These findings provide important new evidence for healthcare professionals, policy makers and immunisation advisory groups considering future influenza vaccination strategies for older adults."

Professor Colin Russell, Chair of the European Scientific Working Group on Influenza (ESWI) and Professor of Applied Evolutionary Biology at Amsterdam University Medical Center, said:

"Influenza vaccine innovation has historically progressed through incremental advances in technology and manufacturing. What makes this study noteworthy is that it shows the potential benefit of bringing multiple proven approaches together in a single vaccine."

"Given the continued burden of influenza-related illness, hospitalisation and death among older adults despite widespread vaccination, these findings represent an important contribution to ongoing efforts to improve protection in this vulnerable population."

About the Phase 3 Study

The randomised, observer-blind Phase 3 immunogenicity study enrolled 7,699 adults aged 50 years and older across Canada, Denmark, Estonia, Germany, Pakistan, the Philippines, the United Kingdom and the United States. Participants received either the MF59-adjuvanted cell-derived higher dose quadrivalent vaccine, an MF59-adjuvanted egg-based quadrivalent influenza vaccine or a recombinant quadrivalent influenza vaccine. The study evaluated immunogenicity, safety and manufacturing consistency.

About aQIVc

aQIVc is an MF59-adjuvanted, cell-based higher-dose quadrivalent influenza vaccine developed for adults aged 50 years and older.  The trivalent formulation has been licensed for use in people aged 50 and above in the UK and by the European Medicines Agency where it is marketed as AUJEMFLU.®

The vaccine combines three proven approaches designed to enhance protection in older adults:

- MF59 adjuvant technology

- Cell-based manufacturing

- A higher dose formulation versus standard dose influenza vaccines

- Each dose contains 45 micrograms of haemagglutinin per influenza strain and 19.5 mg of MF59 adjuvant2

About CSL Seqirus

CSL Seqirus is part of CSL (ASX: CSL). As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness and response. With state-of-the-art production facilities in the US, the UK and Australia, CSL Seqirus utilises egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world. For more information about CSL Seqirus, visit www.CSL.com.

Intended Audience

This press release is issued by CSL Seqirus and is intended to provide information about our global business. Information relating to the approval status, product labels, recommendations and availability of CSL Seqirus products may vary from country to country. Please consult your local regulatory authority for information on approval status and local prescribing information.

Forward-Looking Statements

This press release may contain forward-looking statements, including statements regarding future results, performance, regulatory milestones, product availability or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these uncertainties, you should not place undue reliance on forward-looking statements.

For more information, please contact:

MEDIA CONTACT 

Alex Kiefer

[email protected]

Director International & Pandemic Communications, CSL Seqirus 

GL-aTIVc-26-0011

References

1 Essink BJ, Vermeulen W, Andrade C, Mazur M, de Rooij R, Heijnen E, et al. Immunogenicity and safety of an MF59-adjuvanted cell-derived higher-dose quadrivalent influenza vaccine (aQIVc) in adults aged 50 years or older: a phase 3 randomised controlled trial. Lancet Infect Dis. In press 2026. Volume 26. September 2026.  THELANCETID-D-26-00167R3.

2 Aujemflu suspension for injection in pre-filled syringe: summary of product characteristics [Internet]. Maidenhead: Seqirus UK Limited; 4 June 2026 (PL 47991/0020). Available from: https://www.medicines.org.uk/emc/product/102343/smpc cited 2026 Aug 2.

3 Ashraf M, Boivin W, Nguyen-Van-Tam JS, Nolan T, Stein AN, Russell CA. Development of an adjuvanted, higher-dose, cell-based influenza vaccine: combining advanced technologies to improve vaccine effectiveness. Expert Rev Vaccines. 2026;25(1):2667732. doi:10.1080/14760584.2026.2667732.

4 World Health Organization. Influenza (seasonal): fact sheet [Internet]. Geneva: WHO; 28 February 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)  cited 2026 Aug 28.

5 Cadar AN, Martin DE, Bartley JM. Targeting the hallmarks of aging to improve influenza vaccine responses in older adults. Immun Ageing. 2023;20:23. doi:10.1186/s12979-023-00348-6.

6 Essink BJ, Vermeulen W, Andrade C, de Rooij R, Isakov L, Casula D, et al. A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older. Vaccine. 2025;51:126791. doi:10.1016/j.vaccine.2025.126791.

7 de Looze F, Essink BJ, van Boxmeer J, Andrade C, de Rooij R, Casula D, et al. Immunogenicity and safety of higher-dose cell-based adjuvanted quadrivalent influenza vaccines: combined results of randomised, controlled dose-finding and dose-confirmation studies. Vaccine. 2026;79:128436. doi:10.1016/j.vaccine.2026.128436.

8 Ashraf M, Stein AN, Youhanna J, Rockman S, McMahon M, McGovern I, et al. The impact of egg adaptation and immune imprinting on influenza vaccine effectiveness. Vaccine. 2025;62:127393. doi:10.1016/j.vaccine.2025.127393.

9 Monto AS, Petrie JG, Cross RT, Johnson E, Liu M, Zhong W, et al.

NEW YORK, Sept. 10, 2026 /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of TruBridge, Inc. (NASDAQ: TBRG) resulting from allegations that TruBridge may have issued materially misleading business information to the investing public.

So what: If you purchased TruBridge securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=56548 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On March 17, 2026, TruBridge filed a Notification of Late Filing on Form 12b-25, in which it stated that TruBridge was unable to file its Annual Report for the fiscal year ended December 31, 2025. The report stated its inability to file was a result of "the identification of out-of-period errors of previously issued financial statements and the consequential need to complete certain related analyses." In addition, the report stated that "the Company's management identified errors in the Company's previously issued consolidated financial statements, including for the years ended December 31, 2024 and December 31, 2023, as well as out-of-period errors in the condensed financial statements for the quarters ended March 31, June 30, and September 30, 2025. These errors relate to revenue recognition and related contract cost, stock-based compensation expense, and capitalized software development expense. As a result, the Company is required to make revisions to its previously issued consolidated financial statements for the years ended December 31, 2024 and December 31, 2023, filed with its Annual Reports on Form 10-K for the years then ended, in order to recognize certain of such revenues, costs and expenses in the appropriate fiscal year."

On this news, TruBridge's stock price fell $1.84 per share, or 10.5%, to close at $15.75 per share on March 17, 2026.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.

     Phillip Kim, Esq.

     The Rosen Law Firm, P.A.

     275 Madison Avenue, 40th Floor

     New York, NY 10016

     Tel: (212) 686-1060

     Toll Free: (866) 767-3653

     Fax: (212) 202-3827

     [email protected]

     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Share this article

Endorsed by leading international type 1 diabetes associations, guidance provides clear actions for integrating screening into the healthcare setting

NEW YORK, Sept. 10, 2026 /PRNewswire/ -- A Breakthrough T1D-convened paper published today in Diabetologia titled "International consensus guidance for general population screening for islet autoantibodies to diagnose early-stage type 1 diabetes" outlines the first framework for implementing general population screening for type 1 diabetes (T1D) in clinical practice. The guidance was developed by nearly 30 leading T1D experts from around the globe and is backed by a robust body of evidence that demonstrates the value of screening for T1D. Designed for healthcare professionals, the guidance provides clear pathways for identifying who should be screened for T1D, when screening should occur, and how often.

T1D develops in stages, over time, and can be detected long before symptoms are present and insulin therapy is required. A simple blood test can detect the presence of islet autoantibodies, which signal that the body's immune system is attacking insulin-producing cells. If a person has two or more persistent autoantibodies, they are in stage 1 or 2 T1D, and it is very likely they'll develop clinical, stage 3 T1D.

The new consensus screening guidance states that screening for T1D should begin in young children aged 2-4 years, with rescreening of children who test negative at ages 6-8 years and again at 10-15 years, aligned with other preventative healthcare visits. It indicates that initial screening results should be confirmed with another test before diagnosis. The new T1D screening guidance builds on and aligns with the consensus monitoring guidance that Breakthrough T1D led in 2024. Together, they provide a comprehensive guide for screening and monitoring for T1D.

Early detection of T1D islet autoantibodies through screening can have significant benefits, including reduced risk of life-threatening complication diabetic ketoacidosis (DKA) at diagnosis, the ability to intervene and delay disease progression through approved therapies, opportunities to access clinical trials for disease-modifying therapies, and time to plan and prepare for future health needs. The ability to detect T1D in its early stages has also led to the development of therapies, like teplizumab, that can delay stage 3 T1D, and catalyzed ongoing research focused on delaying, stopping, and reversing the immune attack that causes T1D.

"Early detection of type 1 diabetes is crucial for the future of T1D care, and this consensus guidance moves us one step closer to a world where everyone is screened and has the opportunity to realize the benefits of screening," said Anastasia Albanese-O'Neill, Ph.D., Breakthrough T1D Vice President of Medical Affairs. "With this consensus guidance, healthcare professionals have the information they need to begin general population screening for type 1 diabetes in their clinical practices. We're grateful to the international experts who provided their time and vast experience in the field to develop this guidance, and we look forward to the positive impact this will have for everyone affected by the disease."

Convened by Breakthrough T1D, the international screening consensus is endorsed and supported by 20 global diabetes societies and organizations including the European Association for the Study of Diabetes, Australian Diabetes Association, International Society of Pediatric and Adolescent Diabetes, Association of Diabetes Care and Education Specialists, Association Belge Du Diabete, Belgian Diabetes Liga, Czech Diabetes Society, Fondazione Italiana Diabete, Pediatric Endocrinology Nursing Society, Portuguese Diabetes Association, Sociedade portuguesa de Diabetologia, Societe Francophone du Diabete, and others.

About Breakthrough T1D, Formerly JDRF

As the leading global type 1 diabetes research and advocacy organization, Breakthrough T1D helps make everyday life with type 1 diabetes better while driving toward cures. We do this by investing in the most promising research, advocating for progress by working with government to address issues that impact the T1D community, and helping educate and empower individuals facing this condition.

About Type 1 Diabetes (T1D)

T1D is an autoimmune condition that causes the pancreas to make very little insulin or none at all. This leads to dependence on insulin therapy and the risk of short and long-term complications, which can include highs and lows in blood sugar; damage to the kidneys, eyes, nerves, and heart; and even death. Globally, it impacts 9.5 million people. Many believe T1D is only diagnosed in childhood and adolescence, but diagnosis in adulthood is common and accounts for nearly 50% of all T1D diagnoses. The onset of T1D has nothing to do with diet or lifestyle. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. There is currently no cure for T1D.

Contact:

Casey Fielder

[email protected]

509-651-0087

SOURCE Breakthrough T1D, Formerly JDRF

Share this article